1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIBIB Trailblazer Award for New and Early Stage Investigators (R21) is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). This grant is for early-stage researchers to pursue projects at the intersection of engineering and the physical sciences with life sciences. It is ideal for high-risk, high-impact medical device research where preliminary data is not required.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: NIH-defined New and Early Stage Investigators at academic institutions or small businesses. Confirm the full requirements in the official notice before applying.
The current listing shows $400,000 over 3 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The most recent published deadline was February 16, 2026, which has passed. This is an annual program, so a new cycle should follow. Check the funder's website for the next application window.
NIBIB Trailblazer Award for New and Early Stage Investigators (R21) is funded by National Institute of Biomedical Imaging and Bioengineering (NIBIB). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Small Business Innovation Research (SBIR)/ Small Business Technology Transfer... is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB Small Business Program supports the translation of cutting-edge technologies into commercial products to address critical healthcare challenges. These programs encourage research and development with a strong potential for technology commercialization.
NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB). NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices is a grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) that funds the translational development of innovative diagnostic and therapeutic medical devices.
NIBIB Trailblazer Award for New and Early Stage Investigators (R21) is a grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH that funds high-risk, high-impact research at the intersection of engineering, physical sciences, and biomedical sciences. Eligible applicants are NIH-defined New or Early Stage Investigators who have not previously submitted R01 or R15 applications. Awards provide $400,000 in direct costs over three years. No preliminary data are required — projects should be exploratory, novel, and non-incremental. Applications are due June 16, 2026.
NIBIB Trailblazer Award for New and Early Stage Investigators in Biomedical AI and Imaging (R21) is sponsored by National Institute of Biomedical Imaging and Bioengineering (NIBIB) - NIH. This award supports new and early-stage investigators pursuing research at the intersection of engineering, physical sciences, and biomedical sciences, with a strong emphasis on AI/ML applications in biomedical imaging and data analysis.
The NIBIB Trailblazer Award (R21) supports new and early-stage investigators pursuing research at the interface of engineering, physical sciences, and biomedical sciences, with a strong emphasis on AI/ML applications in biomedical imaging and data analysis. The award provides up to $400,000 in direct costs over a three-year period. Priority research areas include AI-powered clinical decision support systems, computer-aided diagnosis and screening, natural language processing for medical records, predictive modeling for patient outcomes, radiomics and image segmentation, and early-stage software and tool development. The program is designed to lower barriers for investigators who may lack preliminary data by using an R21 mechanism that supports exploratory and developmental research. NIBIB's AI/ML program supports the design and development of artificial intelligence, machine learning, and deep learning to enhance analysis of complex medical images and data.
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read article